Abstract

BackgroundWhen initiating therapy with disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA), treatment adoptions are recommended if no improvement in disease activity is seen within 3 months, or...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
Erik Rødevand ... Till Uhlig
RMD Open | VOL. 4
Erik Rødevand, et. al.Erik Rødevand ... Till Uhlig
01 Oct 2018
FRI0127 Treatment Targets with First Line Biological Agents in Early and Longstanding Rheumatoid Arthritis Patients
I Duca ... M Barba
Annals of the Rheumatic Diseases | VOL. 74
I Duca, et. al.I Duca ... M Barba
01 Jun 2015
POS1298 RELATIONSHIP BETWEEN DISEASE ACTIVITY BY JADAS-27, SDAI, AND DAS-28 AND SUBSEQUENT CHANGES IN PHYSICAL FUNCTION IN ADULT PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
E Inoue ... T Kawabe
-
E Inoue, et. al.E Inoue ... T Kawabe
23 May 2022
OP0272 EARLY RESPONSE IN RHEUMATOID FACTOR LEVELS PREDICTS SUBSEQUENT CLINICAL RESPONSE TO DISEASE MODIFYING TREATMENT OF RHEUMATOID ARTHRITIS
V Konzett ... D Aletaha
Annals of the Rheumatic Diseases | VOL. 82
V Konzett, et. al.V Konzett ... D Aletaha
30 May 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers